Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tongxieanchang Formula versus pinaverium bromide for diarrhea-predominant irritable bowel syndrome
ChiCTR2000039357Phase 2Recruiting
- Sponsor
- Beijing University of Chinese Medicine East Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Tongxie Anchang Formula and pinaverium in Diarrhea-predominant irritable bowel syndrome (IBS-D) (2 arms), sponsored by Beijing University of Chinese Medicine East Hospital. Primary endpoints: Abdominal pain intensity and Stool form. Started Jan 2020; status: recruiting.
02
Drugs
Tongxie Anchang Formulapinaverium
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR2000039357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039357.